Lonza Group (OTCMKTS:LZAGY) Reaches New 52-Week High - Should You Buy?

Key Points

• Lonza Group shares reached a new 52-week high of $73.66, increasing from the previous close of $70.23 during trading.
• Zacks Research downgraded the stock from a "strong-buy" rating to a "hold" rating, though the average rating remains a "Buy" according to MarketBeat.
• The company's segments include Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients, focusing on the pharmaceutical and biotech markets globally.

Lonza Group Ag (OTCMKTS:LZAGY - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $73.66 and last traded at $73.66, with a volume of 1472 shares. The stock had previously closed at $70.23.

Wall Street Analyst Weigh In

Separately, Zacks Research lowered shares of Lonza Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 22nd. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat, Lonza Group has an average rating of "Buy".

Lonza Group Trading Up 2.1%

The firm's 50-day simple moving average is $69.12 and its two-hundred day simple moving average is $69.03.

Lonza Group Company Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.